Ocumension Biotech

Ocumension Biotech is a leading ophthalmic pharmaceutical platform company in China dedicated to identifying, developing, and commercializing first-in-class or best-in-class ophthalmic therapies. Since its inception in 2018, the company has rapidly built a comprehensive pipeline of over 20 drug candidates covering all major front- and back-of-the-eye diseases. Ocumension utilizes a dual-engine growth strategy, combining strategic in-licensing of globally innovative products with robust internal research and development. The company operates a state-of-the-art manufacturing facility in Huzhou and maintains a strong commercial presence across China. Its flagship products include Yutiq for chronic non-infectious uveitis and various advanced treatments for glaucoma and myopia.